Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on March 26, 2015. The report serves to announce the Company's financial results for the fourth quarter and the full year ended December 31, 2014. The filing references a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The provided text is a cover sheet for the 8-K filing and does not contain specific numerical data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric; these figures are contained in the referenced Exhibit 99.1 press release, which is not included in the input.
Material Changes
The filing does not detail specific material changes or comparisons to prior periods within the text provided. It solely indicates that results for the period ended December 31, 2014, have been announced.
Guidance, Outlook, and Risks
The text does not include management commentary, future guidance, risk factors, or contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 Press Release, as they are absent from this 8-K summary.
- Confirm the Company's current name and status, noting the input metadata lists "ACHIEVE LIFE SCIENCES, INC." while the filing text identifies the registrant as "ONCOGENEX PHARMACEUTICALS, INC."
- Review the full press release for any operational updates or clinical trial milestones associated with the 2014 results.